STEM RIM 366 +11

It rebounded significantly after 5 days. It has been announced that a patent for the application of peptide drugs created from the regenerative induction pharmaceutical development candidate Ledacemtide (HMGB1) derived to Shionogi <4507> has been registered in japan. The patent secures the possibility of developing therapeutic drugs for inflammatory bowel diseases (ulcerative colitis, Crohn's disease). Ledacemtide has shown effects such as suppressing weight loss in animal models of inflammatory bowel diseases and suppressing inflammation.

JIG-SAW 3820 -325

Decreased significantly. For the cumulative third quarter of the fiscal year ending December 2024 (January-September 2024), they have announced an operating profit of 0.444 billion yen, a decrease of 4.6% compared to the same period last year. The Data Control business is performing well, securing an increase in revenue to 2.589 billion yen, up 8.7%. However, due to a focus on strengthening human capital management and exceeding the highest amount of past investment, a decrease in profit occurred. There seems to be caution due to the lower profit growth from the previous second quarter cumulative profit (0.385 billion yen, up 13.7%). Full-year estimates are undisclosed.

FLUTTA 284 +37

It has hit a year-to-date high. The dessert "Acai Bowl" has been selected as one of the 30 candidates for the "2024 U-CAN New Word and Popular Word Award for Contemporary Terms" to be held in 24 years, and is being considered as a buying factor. Acai is a fruit believed to be good for health and is the main product of Frutta Frutta. The New Word and Popular Word Award is scheduled to announce the annual grand prize and top ten on December 2nd. It seems to be bought in anticipation of increased awareness and expanded sales as a result of being selected as a candidate.

CloudW 1537 +189

Marked increase. The company has disclosed that it will enhance its shareholder benefit program, presenting QUO card worth 0.01 million yen to shareholders who hold 300 or more shares for over a year. The reference date is the end of December 25. It was already announced in August that as part of the 10th anniversary commemoration of listing, shareholders who hold 300 or more shares as of the end of December 24 (with no specific holding period) will receive a QUO card worth 0.015 million yen. The operating profit forecast for the September 25 fiscal year is set at 1.608 billion yen, a 20.0% increase from the previous year. The operating profit for the September 24 period was a 16.2% increase to 1.34 billion yen.

Stock code 4591, Ribomic, 85, +5

Significant increase. It has been announced that in the early phase 2 clinical trial of a therapeutic drug targeting pediatric patients (5-14 years old) with cartilage imperfection syndrome, a remarkable effect (increase in growth rate) was confirmed in the low-dose subcutaneous administration group. Out of the 6 participants who completed the trial, 5 have transitioned to a long-term low-dose administration trial, continuing to evaluate the effectiveness and safety of the investigational drug. In addition, the high-dose subcutaneous administration trial has completed registration for 7 participants, with administration started in 4 participants, and the results are expected to be revealed in September next year.

Stock code 4419, Finatext, 883, +18

After a rebound for the first time in 5 days. Smart Plus, a group company based in Chiyoda-ku, Tokyo, has announced the addition of a feature that allows spot purchase of investment trust funds using the 'Eikyu Fumetsu Points' of Saison Card/UC Card issued by Credit Saison <8253>, to the online trading service jointly developed with Saison Investment Trust based in Toshima-ku, Tokyo. The unified buying power is 5,000 yen or more, and it is possible to use cash only, Eikyu Fumetsu Points only, or a combination of cash and Eikyu Fumetsu Points.